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Abstract
Hexavalent chromium or Cr(VI) is a known carcinogen in human beings, though the
exact mechanism of carcinogenicity is still unknown. The same chemical compound is also
found at varying levels in the water sources of more than 200 million Americans. While the
government currently regulates total chromium levels, they have yet to determine a
permissible exposure limit for Cr(VI). There is currently no method of preventative treatment
for the chemical. The focus of this study was to determine the mechanism of carcinogenicity of
Cr(VI) as well as confirm the viability of antioxidants as a preventative treatment. Because of
Cr(VI)’s strong oxidative power, we hypothesized that the chemical causes DNA mutation and
cell death via oxidation and that antioxidants could prevent this from occurring. To test this
theory, we exposed human cell culture to Cr(VI) and samples of Cr(VI) cotreated with either
vitamin C or epigallocatechin gallate (EGCG). An Ames test was also performed to determine
the mutagenicity of Cr(VI) as well as cotreatments of the toxicants with antioxidant.
It was found that Cr(VI) is significantly toxic to cell culture at concentrations of 200 ppb
(parts per billion) or more. Both vitamin C and EGCG blocked this effect at 10 ppm (parts per
million) and 15 ppm, respectively. Neither antioxidant was observed to be cytotoxic when
treated alone. Cr (VI) was also found to be significantly mutagenic at 20 ppb and up. This
mutagenicity was significantly reduced by cotreatment with 20 ppm vitamin C at 200 and 2000
ppb Cr. Vitamin C was not found to be mutagenic when treated individually. With this
combined data, we can conclude that hexavalent chromium is both cytotoxic and mutagenic via
an oxidative mechanism and these effects can be abrogated by antioxidants. Though continued
study is merited, this information further validates the protective potential of antioxidants.
ii

Introduction
Hexavalent Chromium
The toxicological effects of hexavalent chromium (Cr(VI)) compounds have been widely
studied over the years. Specifically, data have been collected to assess its carcinogenic effects
on humans through case study (Yu, 2013), its toxicological effects on rats (Geetha et al., 2003),
and on a number of cellular cultures as well (Majone et al., 2002). While there exist 3 different
oxidative states for chromium, the hexavalent form has been found to be much more toxic than
the quadrivalent form or the trivalent form, which in fact is an essential element for humans
(Sun et al., 2015). Unfortunately, the toxicant can be found in hexavalent form in the tap water
of nearly two thirds of the United States’ drinking supply (Andrews & Walker, 2016). While the
environmental protection agency (EPA) monitors total chromium levels in our water,
hexavalent levels are not monitored, and the toxicant is ingested daily. The EPA’s current
maximum contaminant level (MCL) for total chromium is 100 ppb, however Cr(VI) at 100 ppb
could have detrimental effects on a population. In humans, hexavalent chromium toxicity
through ingestion has been known to cause cardiovascular, gastrointestinal, hematological,
hepatic, renal, and neurological damage, and in severe cases, causes cancer or death (Yu, 2013).
Furthermore, roughly ten percent of inorganic Cr(VI) is absorbed through the intestinal tract
(Yu, 2013). Excretion of absorbed chromium occurs primarily via urine. In humans, the kidney
excretes about 60% of an absorbed Cr(VI) dose in the form of Cr(III) within 8 hours of ingestion.
Approximately 10% of an absorbed dose is eliminated by biliary excretion, with smaller
amounts excreted in hair, nails, milk, and sweat (Kiilunen & Kivisto, 1983). Clearance from
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plasma is generally rapid (within hours), whereas elimination from tissues is slower, with a halflife of several days (ATSDR, 2012).
Chromium is a naturally occurring element and often found in both the hexavalent and
trivalent states in natural watersheds (Loyaux-Lawniczak et al, 2001). However, chromium
compounds are often used for chromium plating and other industrial uses as well (Kamerud et
al., 2013). Disposal of chromium containing commercial products and coal ash from electric
utilities and other industries are major sources of chromium releases into the soil (Barceloux
1999). Solid waste and slag produced during chromate manufacturing processes can be
potential sources of chromium exposure as well (Barceloux 1999). Improper disposal and
maintenance of the chemical at these facilities can cause environmental contamination and
drinking water pollution (Cone, 2009). A recent study done on Illinois water showed that
hexavalent chromium concentrations were actually higher in treated water than those in
untreated water. Cr(VI) levels on surface water were found to be 0.3 ppb, and levels in bedrock
aquifers at 1.1 ppb, whereas those in treated water supplies were 2.4 ppb, indicating that water
treatment practices may ironically play a role in increasing concentrations (Mills & Cobb, 2015).
Mechanism of Toxicity
The mechanism of toxicity of Cr(VI) has been found to be induction of oxidative stress
which further leads to cell toxicity and cell death (Bagchi et al., 2002; Chiu et al., 2010).
Oxidative stress results when reactive oxygen species (ROS), either produced endogenously as a
consequence of normal cellular functions or derived from external sources, cause damage that
exceeds the cell’s ability to resist oxidation (Martindale & Holbrook, 2002). When ROS originate
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from exogenous sources, they are either taken up directly by cells from the extracellular matrix
or produced as a consequence of the cell's exposure to some environmental antagonist
(Martindale & Holbrook, 2002). Transient fluctuations in ROS serve important regulatory
functions such as in aerobic respiration, but when present in high levels, ROS can cause severe
damage to DNA, protein, and lipids (Martindale & Holbrook, 2002). A number of cellular
defense mechanisms have evolved to combat the accumulation of ROS. These include various
non‐enzymatic molecules such as glutathione, and vitamins A, C, and E, as well as enzymatic
scavengers of ROS like superoxide dismutase and catalase (Martindale & Holbrook, 2002).
Unfortunately, these systems of defense are not always adequate to counteract the production
of ROS, resulting in what is termed a state of oxidative stress. Because of its 6+ oxidation state,
Cr(VI) is a very powerful oxidizer.
Ames Assay
Previous study shows that not only are hexavalent chromium compounds carcinogenic,
but they are also directly mutagenic towards deoxyribonucleic acid (DNA) (Petrilli & Deflora,
1976). In this procedure, a genetically engineered strain of Salmonella typhimurium was
exposed to differing solutions to test mutagenic potential. When exposed to a mutagen, this
specific strain of bacteria will revert from a state of auxotrophy (inability to produce the
essential amino acid histidine), to a state of prototrophy (ability to produce histidine). This
genetic reversion allows the bacteria to survive and replicate whereas a lack of mutation will
result in death. Bacterial survival, observed by colorimetric determination of its growth media,
is therefore a direct indicator of DNA mutagenesis. This same study showed that the mutagenic
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effects were caused directly by the Cr(VI) and not due to a metabolic byproduct within the
bacteria (Petrilli & Deflora, 1976).
Reduction Potential
One study showed that the use of certain microorganisms as a biological filter could be
used to lower chromium levels (Thatoi et al., 2014), and several others have shown that
antioxidants have chromium reduction potential against chromium as well (Chrysochoou &
Reeves, 2016; Geetha et al., 2003). Antioxidants lower the oxidation state of chromium from 6+
to the lower, less harmful state of 3+. One study showed that epigallocatechin gallate (EGCG)
directly reduces Cr(VI) in solution (Chrysochoou & Reeves, 2013), while another showed that
Vitamin C also reduces Cr(VI) in solution and in the past has been used as a topical treatment
against Cr(VI) skin exposure (Yu, 2013). A third study tested the effect of antioxidants extracted
from the plant Hippophae rhamnoides on albino rats when co-fed with hexavalent chromium.
Results suggested that rats which had been fed antioxidants along with the chromium
compounds exhibited declines in tumor growth both in size and frequency than those which
had been fed chromium compounds without any antioxidant present (Geetha et al., 2003).
While this study demonstrates that a plant extract with antioxidant properties prevents Cr(VI)induced toxicity at the organismal level, little is known about the effects of specific antioxidants
on cellular culture. To date, there have been no studies of Cr(VI) and antioxidant cotreatment
upon human cell culture, and while antioxidants are known to reduce Cr(VI), there is still
uncertainty in regard to which antioxidants are most effective. Additionally, the extent to which
antioxidants are protective has yet to be elucidated; whether they protect against cytotoxicity
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upon the cell membrane and within the cytoplasm, or if they protect against mutagenesis
within the nucleus as well.

Methods
Cellular culture, compounds, and storage
Human intestinal epithelial (HInEpi) cells were obtained from the American Type Culture
Collection (ATCC) and were sustained on the cell line’s respective ATCC media. Human
embryonic kidney (HEK) cells were obtained from a secondary passage in nitrogen storage in
house at Reed Hall of Science, though the original passage was obtained from Loyola University.
These cells were sustained on Dulbecco’s Modified Eagle Medium with 10% Fetal Bovine
Serum, 1% Penicillin-Streptomycin, and 1% L-Glutamine, all of which were sourced from Sigma
Aldrich. Cells were incubated at 37°C and 5% CO2 and passaged once confluent using trypsinEDTA. Both L-Ascorbic Acid and Epigallocatechin Gallate were obtained from Sigma Aldrich. The
Cr(VI) (hexavalent chromium) compound used for experimentation was potassium chromate,
also obtained from Sigma Aldrich.
Determination of treatment concentration
Experimental Cr(VI) concentrations were tested in magnitudes of 10 ranging from 2 ppb
(parts per billion) to 20,000 ppb to simulate environmental conditions as well as coincide with
previous literature. These concentrations were used for both cell proliferation and Ames
procedures. Antioxidant concentrations were determined through experimentation, starting at
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a 1:1 ratio of antioxidant to Cr(VI) and adjusted accordingly based on response until effects
were seen.
Solution Preparation
Stock solutions of Cr(VI), EGCG and ascorbic acid were prepared by dissolving solute in
double-distilled water at a concentration of 2000 ppm and then filter sterilizing under a filtrated
hood. Once treatment concentrations had been determined as described above, smaller
aliquots of stock solution were mixed with the appropriate cell media to bring the final mixture
to the desired experimental concentration. Experimental solution containing both Cr(VI) and an
antioxidant for cotreatment were prepared by bringing both a Cr(VI) solution and an
antioxidant solution to twice their desired final concentration in media and then adding the two
solutions together to dilute the sample down to its experimental concentration. Stock solutions
were stored at 4°C and were remade several times throughout experimentation to avoid
expiration. Experimental solutions were made within 24 hours of use.
Cellular proliferation assay
All cell culture work was done under a sterile hood. Both the HInEpi and HEK cells were
passaged in T-75 flasks in their untreated, respective media until confluency was reached.
These cells were then passaged onto a 24-well plate and again cultured within their untreated
media until wells reached confluency. Treatment groups were then run in quadruplicate,
allowing for 6 sample groups per plate. Cells were exposed to solution for 72 hours. To depict
qualitative results, photos were taken of wells at points of interest along the way using a Nikon
TXI.
6

After the 72-hour incubation period, media was aspirated and then cells were
trypsinized and suspended in solution. 10 μl of solution was taken from each well and then
mixed with equal parts Trypan blue. After at least a minute to allow for cell staining to occur, 10
μl of cell suspension/trypan stain solution was drawn off and dispensed over a hemocytometer
for counting of viable cells to determine number of cells per treatment group.
Ames assay
Ames test kits were purchased from Environmental Bio-detection Products Inc. (EBPI)
and the assay was carried out according to manufacture instructions. The lyophilized bacterial
culture was suspended in a liquid media (Reagent G) 12-16 hours prior to experimentation.
Once suspended, the bacteria were placed in a shaking incubator at 37°C to replicate and grow
overnight. The following day, experimental samples were prepared by diluting the Cr(VI) stock
solution in sterile water to desired concentrations. Turbidity within the bacterial culture verified
growth and the OD600 of the solution was measured by spectrophotometry. This OD (optical
density) value was then used to bring the bacterial suspension to a desired concentration
through a series of calculations. 3 samples of each treatment group were placed in a 24-well
plate for the bacterial exposure period. Positive, negative and sterility controls were also done
on the exposure plate. Added into each well was the treatment solution, exposure media, and
the bacterial suspension, and the plate was incubated at 37°C for 100 minutes. During
incubation period, a reversion media was prepared for the 96-well plates. After the bacteria
had been incubated for 100 minutes, the plate was removed and solution from each well was
pipetted into a tube containing the premade reversion media. Using loading boats and a
multichannel pipette, each sample was pipetted into 48 wells of a 96-well plate. The 96-well
7

plates were then placed in an incubator at 37°C for 3 days to allow for revertant bacteria to
grow. After the 3 day incubation period, plates were scored by colorimetric determination with
yellow and partial-yellow wells indicating genetic reversion.
Statistical analysis
The statistical analysis for both the cell proliferation data and the Ames assay data were
done by a two-tailed t-test data with p-values < 0.05 determined to be statistically significant.

Results

Cr(VI) was shown to exhibit a negative
dose response when exposed to HEK cells.
Figure 1 shows that the negative control
group of untreated media resulted in 570,000
cells per well after a three-day exposure
period. 200 ppb Cr(VI) solution resulted in
Figure 1: Dose response to Cr(VI) Human
embryonic kidney cells were exposed to
different doses of Cr(VI) ranging from 200
ppb - 1000 ppb. A negative dose response to
Cr(VI) was observed.

383,750 cells per well, and 500 ppb Cr(VI)
resulted in 66,250 cells per well while
1000 ppb completely eradicated all cells in

the treatment group. These data made way for the addition of antioxidants to Cr(VI) solution.
Figure 2 shows that 500 ppb chromium was kept constant while varying concentrations
of vitamin C were added as cotreatment. 50 ppm vitamin C was also run independently as a
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control group and yielded similar cell
counts as the negative control. 500 ppb
Cr(VI) cotreated with 5 ppm VC
increased cells per well from 500 ppb
Cr(VI) alone. These counts were
186,250 and 66,250 respectively. Wells
cotreated with Cr(VI) and 10 ppm VC
yielded 467,500 cells per well and
those cotreated with VC concentrations

Figure 2: Dose response to Cr(VI) and vitamin C
cotreatment. Human embryonic kidney cells were
exposed to cotreated samples of 500 ppb Cr(VI) and
differing concentrations of vitamin C. Likelihood of
survival increased with the addition of vitamin C. Cr(VI)
was completely mitigated by 25ppm vitamin C.

at 25 ppm yielded 590,000 cells per well. There is no statistically significant difference between
the negative control and 50 ppm VC. There is also no significant difference between 500 ppb
Cr(VI) cotreated with 25 ppm VC and the negative control.

Figure 3: Human intestinal epithelial cells exposed to Cr(VI) and vitamin C. Cells were exposed to
untreated cell media (panel A), as well as 500 ppb Cr(VI) (panel B) and 500 ppb Cr(VI) cotreated
with 25 ppm vitamin C (panel C). Cotreatment mitigated nearly all observed effects of Cr(VI). This
result was replicated on human embryonic kidney cells. These images were taken 3 days after
exposure.

These results were replicated qualitatively upon a second cell line. Human Intestinal
epithelial cells were exposed to the same treatment groups as shown in Figures 1 and 2. Due to
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difficulties in the cell counting procedure for this particular line of cells, representative pictures
of treatment groups were taken to serve as alternative results to quantification. Panel B in
Figure 3 depicts 500 ppb Cr(VI) exposure whereas panel C shows cotreatment with 25 ppm VC.
Panels A and C look relatively similar, while panel B shows undeniable cytotoxicity and cell
necrosis.
HEK cells were also
exposed to Cr(VI) solutions
cotreated with EGCG. Figure
4 depicts exposure to 500
ppb Cr(VI) and solutions
cotreated with EGCG ranging
from 5 ppm to 50 ppm. In
this trial, 500 ppb Cr(VI) resulted
in 94,500 cells per well. 500 ppb

Figure 4: Dose response to Cr(VI) and EGCG cotreatment.
Human embryonic kidney cells were exposed to solutions of
500 ppb Cr(VI) cotreated with varying concentrations of EGCG.
As EGCG concentrations increased, cell survival also increased.

Cr(VI) cotreated with 5 ppm EGCG also resulted in 94,500 cells per well. Upon further addition
of EGCG, cell survival increased up to the final treatment group of 500 ppb Cr(VI) with 50 ppm
EGCG which yielded a cell count of 460,250. Negative control in this exposure trial yielded
796,250 cells per well and 50 ppm EGCG, 759,500.
Figure 5 depicts the results of the Ames assay, which was performed identically five
separate times throughout the course of experimentation. As Cr(VI) concentrations increased
from 2 ppb to 2000 ppb, percent mutagenicity increased. Treatment groups of 20, 200 and
2000 ppb were significantly more mutagenic than the negative control. 200 ppb and 2000 ppb
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Cr(VI) cotreated with 20 ppm vitamin C were significantly less mutagenic than their Cr(VI)-only
treated counterparts. 20 ppm vitamin C was not found to be mutagenic itself.

Figure 5: Bacteria exposed to Cr(VI) and vitamin C to test mutagenic potential. Bacterial cultures exposed
to solution containing higher levels of Cr(VI) were more likely to mutate DNA. Those exposed to high levels
of Cr(VI) as well as vitamin C were less likely to mutate. * denotes p-value < 0.05 when compared to
negative control, ** denotes p-value < 0.005 when compared to negative control, # denotes p-value < 0.05
compared to that concentration of Cr(VI) alone.

Discussion
These data suggest that Cr(VI) is cytotoxic via an oxidative mechanism. After exposing
human embryonic kidney cells to a range of Cr(VI) concentrations, we can see that the
contaminant has a direct influence on cell death, with higher concentrations of chromium
leading to a lower likelihood of cell survival (Figure 1). These same results were also observed
qualitatively on Human Intestinal Epithelial cells, with higher concentrations of Cr(VI) leading to
greater cell death. Furthermore, these effects were mitigated by the addition of antioxidants
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within cell solution. Both ascorbic acid and epigallocatechin gallate prevented cytotoxicity and
necrosis (Figures 2 and 4). This evidence suggests that Cr(VI) is indeed cytotoxic via an oxidative
mechanism as the presence of an antioxidant reduced cytotoxicity.
Ascorbic acid was found to be a much more potent protective chemical than
epigallocatechin gallate (Figures 2 and 4). This could be due to the vast difference in the size of
the two molecules as ascorbic acid is much smaller than its counterpart. It’s unclear where the
reduction of Cr(VI) into Cr(III) is occurring, whether inside the cell in the cytoplasm or outside
the cell within the culture media, though it is probable that the majority is occurring in the
media before the toxicant enters the cell.
Data from the Ames assay continues to suggest that Cr(VI) is mutagenic by way of
oxidation. As bacterial strains were exposed to increasing concentrations of the toxicant,
percent mutation increased as well. When exposed to solution cotreated with antioxidant
however, percent mutation was essentially nullified as levels were brought back down to those
observed within the negative control group, regardless of the concentration of Cr(VI). That is,
any group treated with vitamin C exhibited no significant change from the negative control,
even at the highest treated concentration of Cr(VI) (2000 ppb).
Furthermore, neither antioxidant tested was found to be cytotoxic or mutagenic in-andof-itself. This serves as crucial information as the ultimate purpose that they may serve as is a
preventative protectant, pre-treated within a drinking water supply. We cannot pre-treat the
water with a level of protectant so high that it itself becomes a harmful contaminant. This
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concern is needless as both vitamin C and EGCG showed great protective potential at levels at
which they themselves were harmless.
It appears that Cr(VI) is more mutagenic towards bacterial DNA at lower concentrations
(20 ppb) than it is cytotoxic towards mammalian cells (200 ppb). This result indicates that
bacterial cells are either more sensitive to Cr(VI), or that mutagenicity is also occurring in the
mammalian cells at concentrations like that in the bacteria, but that the mutations occurring
are nonlethal or nonharmful. In either case, the information merits further research into Cr(VI)
mutagenicity in a mammalian cell line.
Additionally, this study focused on the cotreatment of antioxidants with Cr(VI).
Specifically, both bacterial cells in the Ames test and human cells in the cell proliferation assay
were exposed to both the toxicant and the protectant simultaneously. In both assays, the
cotreated solution was prepared 1-10 hours before cell exposure. Because of this, the chemical
interaction taking place between the two compounds likely occurs in solution. Another
interesting continuation of this study would be examining the differences between a
cotreatment with antioxidant (as performed here in this study) and a pre-treatment or posttreatment with antioxidant.
These data come to the scene at a point in time where millions of Americans are
exposed to hexavalent chromium in their daily water supply (Andrews & Walker, 2016). The
protective potential of antioxidants is promising, and applications of this research are
numerous. For example, just as many European countries began adding fluoride to public water
supplies in the early 90’s to prevent dental caries, antioxidant may be added to water supplies
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known to have higher concentrations of Cr(VI), or areas at higher risk of Cr(VI) contamination.
This reduction potential may also be applied to mitigate other powerful oxidizers. Though
continued study is merited, this information further validates the protective potential of
antioxidants and will be helpful for government agencies and organizations in determining safe
levels of water chromium.
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